Impella ECP Pivotal Study Results Highlight Efficacy
Recent results from a significant study on Impella ECP™, a new transvalvular axial flow pump, were showcased at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference. This revolutionary technology, developed by Abiomed, part of Johnson & Johnson MedTech, serves as a leader in heart recovery.
Pivotal Study Overview and Key Findings
The pivotal investigational device exemption (IDE) study involved 256 patients across 18 sites in the US, and it successfully achieved its primary endpoint. The rate of Major Adverse Cardiac and Cerebrovascular Events (MACCE) at 30 days was recorded at 6.3%. This rate was significantly lower than the previously established performance goal. The Impella ECP technology showed notable safety and efficacy for high-risk PCI procedures.
Success Stories from the Study
Within the study, the operators opted for the 8Fr Angio-Seal as the first closure method in 70% of the cases, achieving an impressive success rate of 92%. Principal Investigator, Dr. Amir Kaki, who leads Mechanical Circulatory Support and Complex Coronary Intervention at Henry Ford - St. John Hospital, commented, "The study met its prespecified 30-day primary endpoint with low complication rates. The 9Fr arterial access facilitated a high success rate in closing with the 8Fr Angio-Seal. Impella ECP technology with small-bore access and closure provides distinct advantages for both patients and physicians."
Design Features of Impella ECP Technology
The Impella ECP pump is ingeniously designed to be both implanted and removed using small bore access techniques. Upon insertion, it expands to a size of 21Fr, delivering essential circulatory support and relieving left ventricular (LV) pressure, making it especially valuable in high-risk PCI scenarios.
Future Directions for Impella ECP
While Impella ECP is currently classified as an investigational device and is restricted by federal law for investigational use only, it is part of an FDA-approved continuous access program at select US sites. The next logical step is for Impella ECP to be submitted to the US FDA for formal approval, paving the way for its broader use in clinical practices.
About Cardiovascular Innovations by Johnson & Johnson MedTech
Johnson & Johnson is at the forefront of tackling the complex health challenges of today. With a comprehensive cardiovascular portfolio, they provide healthcare professionals with state-of-the-art tools for mapping, navigation, and precise intervention techniques. Their commitment to addressing conditions such as heart failure and coronary artery disease has solidified them as a global leader in heart recovery and circulatory restoration.[...]
About Johnson & Johnson
At Johnson & Johnson, the philosophy that health is everything drives their innovative healthcare solutions. The company's strength in addressing complex diseases empowers advancements in treatments that are less invasive and tailored to individual patient needs. Their broad expertise in Innovative Medicine and MedTech allows for the innovative development of a variety of healthcare solutions aimed at improving global health outcomes.[...]
Frequently Asked Questions
What is the Impella ECP technology?
Impella ECP is a novel transvalvular axial flow pump designed to provide circulatory support during high-risk PCI procedures.
What were the results of the pivotal study?
The study demonstrated a MACCE rate of 6.3% at 30 days, significantly lower than the pre-defined goals, confirming the safety and efficacy of Impella ECP.
How was the study conducted?
The study enrolled 256 patients at 18 US sites and was led by Dr. Amir Kaki, focusing on the pump's performance and patient outcomes.
What are the advantages of Impella ECP?
This device uses small-bore access techniques, which enhances patient safety and reduces complication rates during PCI procedures.
What’s next for Impella ECP technology?
The technology will soon be submitted to the US FDA for approval, aiming for wider clinical adoption and use.
